Preclinical investigation of orally bioavailable, potent KRASMulti inhibitor JAB-23425

被引：0
|
作者：
Wang, Peng
Wang, Yanping
Sun, Xin
Liu, Dan
Liu, Xiaoyu
Zhang, Wei
He, Xueting
Zhou, Rui
Ma, Cunbo
Li, Amin
Lin, Yiwei
Long, Wei
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-1660
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1660
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor
    Caenepeel, Sean
    Karen, Rex
    Belmontes, Brian
    Verlinsky, Alla
    Tan, Hong
    Yang, Yajing
    Chen, Xiaoyue
    Li, Kexue
    Allen, Jennifer
    Wahlstrom, Jan
    Canon, Jude
    Coxon, Angela
    Hughes, Paul
    CANCER RESEARCH, 2020, 80 (16)
  • [2] Preclinical metabolism and disposition of an orally bioavailable macrocyclic FXIa inhibitor
    Chacko, Silvi A.
    Yang, Wu
    Wang, Yufeng
    Tian, Yuan
    Hong, Yang
    Wallace, Michael
    Wang, Bonnie
    Ewing, William R.
    Luettgen, Joseph M.
    Shu, Yue-Zhong
    Christopher, Lisa J.
    XENOBIOTICA, 2021, 51 (08) : 933 - 948
  • [3] Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor
    Zhang, Hefeng
    Peng, Xia
    Dai, Yang
    Shao, Jingwei
    Ji, Yinchun
    Sun, Yiming
    Liu, Bo
    Cheng, Xu
    Ai, Jing
    Duan, Wenhu
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (07) : 3956 - 3975
  • [4] Preclinical studies of TSN1611, a potent, selective, and orally bioavailable KRASG12D inhibitor
    Shang, Erchang
    Zhong, Boyu
    Zhang, Tony
    Dong, Chunlan
    Ma, Shengtang
    Yang, Anjiang
    Jia, Ziyang
    Zheng, Renjuan
    Li, Jing
    Fu, Han
    Lai, Liangbao
    CANCER RESEARCH, 2024, 84 (06)
  • [5] PRECLINICAL PHARMACOKINETICS AND METABOLISM OF A FIRST-IN-CLASS, POTENT AND ORALLY BIOAVAILABLE EED INHIBITOR EED226
    Zhang, Jiyue
    DRUG METABOLISM AND PHARMACOKINETICS, 2018, 33 (01) : S42 - S42
  • [6] KRASmulti inhibitor BI 3706674, an orally bioavailable, direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in KRASG12V-driven preclinical models
    Peng, David Hwa
    Tedeschi, Antonio
    Herdeis, Lorenz
    Schaaf, Otmar
    Savarese, Fabio
    Rocchetti, Francesca
    Popow, Johannes
    Huber, Heinrich J.
    Wilding, Birgit
    Treu, Matthias
    Fuchs, Julian
    Broeker, Joachim
    Wunberg, Tobias
    Schischlik, Firoella
    Lipp, Jesse
    Williams, Mariah
    Chandler, Vaness
    Deckard, Charles E.
    Ramamoorthy, Vandhana
    Daniele, Joseph R.
    Kopetz, Scott
    Kim, Michael
    Gibbons, Don L.
    Vellano, Christopher P.
    Marszalek, Joseph R.
    Heffernan, TImothy P.
    McConnell, Darryl
    Pearson, Mark
    Kraut, Norbert
    Rudolph, Dorothea
    CANCER RESEARCH, 2024, 84 (06)
  • [7] PRECLINICAL CHARACTERIZATION OF THE NOVEL, ORALLY BIOAVAILABLE NTCP INHIBITOR A7387
    Strangberg, Ellen
    Bonn, Britta
    Phuong Phan
    Uzelac, Ivana
    Starke, Ingemar
    Pal, Runa
    Gaur, Ashwani
    Kangarajan, Ramesh
    Singh, Shivendra
    Kulkarni, Santosh
    Dawson, Paul A.
    Lindstrom, Erik
    HEPATOLOGY, 2023, 78 : S582 - S582
  • [8] Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
    Pancras C. Wong
    Donald J. P. Pinto
    Donglu Zhang
    Journal of Thrombosis and Thrombolysis, 2011, 31 : 478 - 492
  • [9] Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
    Wong, Pancras C.
    Pinto, Donald J. P.
    Zhang, Donglu
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2011, 31 (04) : 478 - 492
  • [10] The first total synthesis of (±)-arisugacin A, a potent, orally bioavailable inhibitor of acetylcholinesterase
    Sunazuka, T
    Handa, M
    Nagai, K
    Shirahata, T
    Harigaya, Y
    Otoguro, K
    Kuwajima, I
    Omura, S
    ORGANIC LETTERS, 2002, 4 (03) : 367 - 369
12345